News Year None202620252024202320222021202020192018201720162015201420132012 May 12, 2026 Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update May 5, 2026 Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026 May 4, 2026 OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026 April 13, 2026 Lineage Announces Formation of Scientific Advisory Board March 24, 2026 Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease March 5, 2026 Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update February 26, 2026 Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026 January 6, 2026 Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience January 5, 2026 Lineage Cell Therapeutics Issues Letter to Stockholders
May 12, 2026 Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 5, 2026 Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026
May 4, 2026 OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026
March 5, 2026 Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 26, 2026 Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026
January 6, 2026 Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience
